Home › Companies › KURA

Kura Oncology, Inc.

KURA Lead: Phase 1 1 Biotech Distilled article ↓

Metabolic Oncology Small Molecule

Most recent annual filing: 2026-03-05

Pipeline (9 active programs)

KOMZIFTI

ziftomenib

Small Molecule Target: menin, KMT2A, FLT3

Acute Myeloid Leukemia Phase 1 oral Kyowa Kirin
Pediatric Acute Leukemia Phase 1 oral Blood Cancer United
Gastrointestinal Stromal Tumor Phase 1 oral

KO-7246

Small Molecule Target: menin

darlifarnib

Small Molecule Target: farnesyl transferase, KRAS G12C

Renal Cell Carcinoma Phase 1 oral
Non-Small Cell Lung Cancer Phase 1 oral Mirati Therapeutics
Colorectal Cancer Phase 1 oral Mirati Therapeutics
Pancreatic Ductal Adenocarcinoma Phase 1 oral Mirati Therapeutics

Discontinued (1)

tipifarnib — Head and Neck Squamous Cell Carcinoma · KURRENT-HN trial completed in Q3 2025; evaluating data generation options for next steps with darlifarnib combination

Biotech Distilled coverage (1)

2026-05-15 Kura Oncology (KURA) - Scientific Deep Dive for Ziftomenib and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.